Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec;12(12):3079-3088.
doi: 10.1080/21645515.2016.1221872.

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1

Affiliations
Clinical Trial

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1

Julie L Dutton et al. Hum Vaccin Immunother. 2016 Dec.

Abstract

This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and protect against lethal herpes simplex virus type 2 (HSV-2) challenge in mice. Five escalating doses of the vaccine, COR-1, were given by intradermal injection to HSV-1 and 2 seronegative healthy individuals. COR-1 was found to be safe and well-tolerated; the only vaccine-related adverse events were mild. While vaccine-induced antibody responses were not detectable, cell-mediated immune responses to HSV-specific peptide groups were identified in 19 of the 20 subjects who completed the study, and local inflammation at the immunisation site was observed. This study indicates COR-1 has potential to be used as a therapeutic vaccine for HSV-2 infection.

Keywords: DNA vaccine; Genital herpes; HSV-2; codon-modification; healthy volunteers; polynucleotide vaccine; ubiquitination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Disposition of subjects. N = number of subjects.
Figure 2.
Figure 2.
Injection site reactions. Scores corresponding to the injection site erythema size, measured 1 (A) and 2 (B) days after each vaccination, are plotted for subjects of cohorts that received 500 μg to 30 μg DNA vaccine. Note that the cohort which received 1 mg of DNA vaccine received 2 injections of 500 μg to both forearms. Scores of 1, 2, 3 and 4 were given for erythema measuring ∼0.5, ∼1.0, ∼1.5 and >1.5 cm, respectively.
Figure 3.
Figure 3.
Pre-existing and vaccine-related cellular responses measured by IFN-γ ELISPOT. (A) Pre-existing responses to the gD2 peptide were determined using PBMCs taken at Visit 1 before the first vaccination. Responses were determined positive if X-(SD of X) – Y-(2xST of Y) > 10 (X: mean spot value; Y: mean spot value of no peptide control wells). (B) Number of subjects that were classified of having mounted a vaccine-related cellular immune response to gD2. Vaccine related positivity was accepted when the mean spot value was increased at least 2 fold compared to pre-existing responses in at least one peptide pool and at least one visit after vaccination.

Similar articles

Cited by

References

    1. Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992–2006. Sex Transm Infect 2009; 85:416-9; PMID:19273479; http://dx.doi.org/10.1136/sti.2008.033902 - DOI - PubMed
    1. Haddow LJ, Dave B, Mindel A, McPhie KA, Chung C, Marks C, Dwyer DE. Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003. Sex Transm Infect 2006; 82:255-9; PMID:16731681; http://dx.doi.org/10.1136/sti.2005.018176 - DOI - PMC - PubMed
    1. Tran T, Druce JD, Catton MC, Kelly H, Birch CJ. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect 2004; 80:277-9; PMID:15295125; http://dx.doi.org/10.1136/sti.2004.009753 - DOI - PMC - PubMed
    1. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83; PMID:16327322; http://dx.doi.org/10.1097/01.aids.0000198081.09337.a7 - DOI - PubMed
    1. Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res 2012; 10:228-37; PMID:22384842; http://dx.doi.org/10.2174/157016212800618156 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources